ALENDRONIC ACID
Metabolic Bone Disorder
McMaster UniversitySmall moleculePhase 4 / ApprovedDormant
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Metabolic Bone Disorder cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
VITAMIN D University of Sao Paulo General Hospital | Phase 4 | BB |
Biktarvy Saskatchewan Health Authority - Regina Area | Phase 4 | BB |
Genvoya Saskatchewan Health Authority - Regina Area | Phase 4 | BB |
Epclusa Saskatchewan Health Authority - Regina Area | Phase 4 | BB |
Gip Esbjerg Hospital - University Hospital of Southern Denmark | N/A | D |
Same molecule, other indications
ALENDRONIC ACID is also rated in:
metabolic dysfunction-associated steatotic liver diseaseActive
B
Indicative · Phase 4
62 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →